{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:45:54Z","timestamp":1778287554884,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CBER"},{"name":"FDA MCMi"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.yrtph.2016.08.003","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T03:46:54Z","timestamp":1470368814000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice"],"prefix":"10.1016","volume":"81","author":[{"given":"Million A.","family":"Tegenge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Von Tungeln","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Mitkus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Vanlandingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick A.","family":"Beland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2016.08.003_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/icb.2010.10","article-title":"Queries about vaccines containing squalene","volume":"88","author":"Beck","year":"2010","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.yrtph.2016.08.003_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10637-006-5383-1","article-title":"Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection","volume":"24","author":"Boswell","year":"2006","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.yrtph.2016.08.003_bib3","doi-asserted-by":"crossref","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.yrtph.2016.08.003_bib4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0264-410X(99)00263-7","article-title":"Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice","volume":"18","author":"Dupuis","year":"1999","journal-title":"Vaccine"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.yrtph.2016.08.003_bib5","doi-asserted-by":"crossref","first-page":"B163","DOI":"10.1016\/j.vaccine.2012.10.117","article-title":"A\u00a0global regulatory science agenda for vaccines","volume":"31","author":"Elmgren","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2016.08.003_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.08.003_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF02353461","article-title":"Analysis of animal pharmacokinetic data: performance of the one point per animal design","volume":"23","author":"Ette","year":"1995","journal-title":"J.\u00a0Pharmacokinet. Biopharm."},{"key":"10.1016\/j.yrtph.2016.08.003_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0022-1759(03)00081-4","article-title":"A\u00a0simple and rapid vortex method for preparing antigen\/adjuvant emulsions for immunization","volume":"276","author":"Flies","year":"2003","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.yrtph.2016.08.003_bib9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/14760584.2013.811188","article-title":"An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants","volume":"12","author":"Fox","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.yrtph.2016.08.003_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Garcon","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.yrtph.2016.08.003_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/erv.11.170","article-title":"Aflunov((R)): a prepandemic influenza vaccine","volume":"11","author":"Gasparini","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.yrtph.2016.08.003_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0021-9150(94)90122-8","article-title":"Postabsorptive metabolism of dietary squalene","volume":"106","author":"Gylling","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yrtph.2016.08.003_bib13","doi-asserted-by":"crossref","first-page":"15ra5","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yrtph.2016.08.003_bib14","doi-asserted-by":"crossref","first-page":"e95496","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2016.08.003_bib15","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yrtph.2016.08.003_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2014.11.018","article-title":"Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial","volume":"33","author":"Langley","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2016.08.003_bib17","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.yrtph.2016.08.003_bib18","doi-asserted-by":"crossref","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","article-title":"New generation adjuvants\u2013from empiricism to rational design","volume":"33","author":"O'Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2016.08.003_bib19","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59-an innately attractive adjuvant formulation","volume":"30","author":"O'Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2016.08.003_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","article-title":"MF59. Design and evaluation of a safe and potent adjuvant for human vaccines","volume":"6","author":"Ott","year":"1995","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.yrtph.2016.08.003_bib21","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.4155\/bio.13.147","article-title":"Application of population pharmacokinetics for preclinical safety and efficacy studies","volume":"5","author":"Porzio","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.yrtph.2016.08.003_bib22","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jat.3130","article-title":"Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines","volume":"35","author":"Segal","year":"2015","journal-title":"J.\u00a0Appl. Toxicol."},{"key":"10.1016\/j.yrtph.2016.08.003_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10928-013-9328-y","article-title":"A\u00a0physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines","volume":"40","author":"Tegenge","year":"2013","journal-title":"J.\u00a0Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.yrtph.2016.08.003_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.yrtph.2015.02.005","article-title":"A\u00a0first-generation physiologically based pharmacokinetic (PBPK) model of alpha-tocopherol in human influenza vaccine adjuvant","volume":"71","author":"Tegenge","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.08.003_bib25","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2016.08.003_bib26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0005-2760(82)90355-1","article-title":"Fate of intravenously administered squalene in the rat","volume":"712","author":"Tilvis","year":"1982","journal-title":"Biochimica Biophysica Acta (BBA)-Lipids Lipid Metabolism"},{"key":"10.1016\/j.yrtph.2016.08.003_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF02534687","article-title":"Dietary squalene increases tissue sterols and fecal bile acids in the rat","volume":"18","author":"Tilvis","year":"1983","journal-title":"Lipids"},{"key":"10.1016\/j.yrtph.2016.08.003_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.vaccine.2015.01.073","article-title":"Safety of vaccine adjuvants: focus on autoimmunity","volume":"33","author":"van der Laan","year":"2015","journal-title":"Vaccine"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323001630215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323001630215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T15:43:38Z","timestamp":1616600618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323001630215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":28,"alternative-id":["S027323001630215X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2016.08.003","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2016.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}